|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
JP6054742B2
(ja)
|
2009-07-13 |
2016-12-27 |
ジーランド ファーマ アクティーゼルスカブ |
アシル化グルカゴン類似体
|
|
EP3323423B1
(en)
|
2009-09-28 |
2020-06-17 |
Intarcia Therapeutics, Inc |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
|
US20120329711A1
(en)
*
|
2009-12-16 |
2012-12-27 |
Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
|
JP6231386B2
(ja)
|
2010-11-09 |
2017-11-15 |
ノヴォ ノルディスク アー／エス |
リンカーを有する二重アシル化されたｇｌｐ−１誘導体
|
|
MX377589B
(es)
|
2010-12-16 |
2025-03-10 |
Novo Nordisk As |
Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
|
|
US20120208755A1
(en)
*
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
AU2012241894B2
(en)
|
2011-04-12 |
2015-12-03 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
|
AU2012286048A1
(en)
|
2011-07-18 |
2014-02-20 |
Arts Biologics A/S |
Long acting luteinizing hormone (LH) compound
|
|
JP6126097B2
(ja)
*
|
2011-09-06 |
2017-05-10 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体
|
|
CN110041399B
(zh)
|
2011-12-29 |
2023-12-12 |
诺沃—诺迪斯克有限公司 |
包含非成蛋白质性的氨基酸的二肽
|
|
ES2810153T3
(es)
|
2012-03-01 |
2021-03-08 |
Novo Nordisk As |
Profármacos de GLP-1
|
|
KR102072202B1
(ko)
|
2012-03-22 |
2020-01-31 |
노보 노르디스크 에이/에스 |
Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
|
|
ES2715308T3
(es)
|
2012-03-22 |
2019-06-03 |
Novo Nordisk As |
Composiciones que comprenden un agente de suministro y su preparación
|
|
CA2872314C
(en)
|
2012-05-03 |
2021-08-31 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
CN104411322B
(zh)
*
|
2012-05-08 |
2017-05-24 |
诺和诺德股份有限公司 |
双酰化glp‑1衍生物
|
|
EP2846823B1
(en)
|
2012-05-08 |
2019-12-04 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
EP2851429B1
(en)
|
2012-05-18 |
2019-07-24 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
|
WO2013189988A1
(en)
|
2012-06-20 |
2013-12-27 |
Novo Nordisk A/S |
Tablet formulation comprising a peptide and a delivery agent
|
|
HUE049152T2
(hu)
|
2012-07-01 |
2020-09-28 |
Novo Nordisk As |
Hosszantartó hatású GLP-1 peptidek alkalmazása
|
|
NZ704043A
(en)
|
2012-07-23 |
2017-07-28 |
Zealand Pharma As |
Glucagon analogues
|
|
FR2994848B1
(fr)
|
2012-08-30 |
2014-08-22 |
Univ Paris Curie |
Traitement de l'arthrose par les hormones incretines ou leurs analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
US9637517B2
(en)
|
2012-10-31 |
2017-05-02 |
Hybio Pharmaceutical Co., Ltd. |
Method for preparing exenatide
|
|
HUE035803T2
(en)
|
2012-12-21 |
2018-05-28 |
Sanofi Sa |
Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
|
|
RS58039B1
(sr)
|
2013-05-02 |
2019-02-28 |
Novo Nordisk As |
Oralno doziranje glp-1 jedinjenja
|
|
AU2014283221A1
(en)
*
|
2013-06-20 |
2015-12-03 |
Novo Nordisk A/S |
GLP-1 derivatives and uses thereof
|
|
JP6139712B2
(ja)
|
2013-07-04 |
2017-05-31 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１様ペプチドの誘導体及びその使用
|
|
CN105451776B
(zh)
|
2013-08-15 |
2020-04-17 |
诺和诺德股份有限公司 |
Glp-1衍生物及其用途
|
|
WO2015038938A1
(en)
|
2013-09-13 |
2015-03-19 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
AR098065A1
(es)
|
2013-10-17 |
2016-04-27 |
Zealand Pharma As |
Análogos de glucagón acilados
|
|
AU2014345570B2
(en)
|
2013-11-06 |
2019-01-24 |
Zealand Pharma A/S |
Glucagon-GLP-1-GIP triple agonist compounds
|
|
CA2929459C
(en)
|
2013-11-06 |
2022-05-03 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
WO2015081891A1
(en)
|
2013-12-06 |
2015-06-11 |
Baikang (Suzhou) Co., Ltd |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／升糖素受體促效劑
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
US10039809B2
(en)
|
2013-12-18 |
2018-08-07 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
WO2015155151A1
(en)
*
|
2014-04-07 |
2015-10-15 |
Novo Nordisk A/S |
Double-acylated glp-1 compounds
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
*
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
BR122021025449B1
(pt)
|
2014-06-12 |
2024-02-15 |
Ra Pharmaceuticals, Inc |
Composto, polipeptídeo e composição compreendendo o mesmo
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
EP3212218B1
(en)
|
2014-10-29 |
2021-06-30 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
|
JP6730278B2
(ja)
*
|
2014-11-27 |
2020-07-29 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体及びその使用
|
|
EP3233898A1
(en)
|
2014-12-17 |
2017-10-25 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
SMT202100688T1
(it)
|
2015-01-28 |
2022-01-10 |
Ra Pharmaceuticals Inc |
Modulatori di attività del complemento
|
|
JP7211704B2
(ja)
*
|
2015-01-29 |
2023-01-24 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
|
|
WO2016120380A1
(en)
*
|
2015-01-29 |
2016-08-04 |
Novo Nordisk A/S |
Pharmaceutical composition for oral glp-1 administration comprising a tablet core and immediate release coating
|
|
PL3283507T3
(pl)
|
2015-04-16 |
2020-05-18 |
Zealand Pharma A/S |
Acylowany analog glukagonu
|
|
ES2968262T3
(es)
|
2015-06-03 |
2024-05-08 |
I2O Therapeutics Inc |
Sistemas de colocación de implantes
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
US10118904B2
(en)
|
2015-06-05 |
2018-11-06 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of Demyelinating Diseases
|
|
HUE057041T2
(hu)
|
2015-07-06 |
2022-04-28 |
Alkermes Inc |
Hiszton deacetiláz hetero-halogén gátlói
|
|
WO2017007755A1
(en)
|
2015-07-06 |
2017-01-12 |
Rodin Therapeutics, Inc. |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|
|
CN106496322A
(zh)
*
|
2015-09-07 |
2017-03-15 |
江苏恒瑞医药股份有限公司 |
人胰岛素或其类似物的酰化衍生物的制备方法
|
|
CN108473547A
(zh)
*
|
2015-10-28 |
2018-08-31 |
塔夫茨大学 |
具有改良的蛋白质分解安定性的新颖多肽，以及制备与使用该新颖多肽的方法
|
|
KR20260070290A
(ko)
|
2015-12-16 |
2026-05-18 |
유씨비 홀딩스 인코포레이티드 |
보체 활성의 조절인자
|
|
GB2551945B
(en)
*
|
2015-12-18 |
2021-09-08 |
Heptares Therapeutics Ltd |
Novel GLP-1 receptor agonist peptides
|
|
WO2017149070A1
(en)
|
2016-03-03 |
2017-09-08 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
KR20240037175A
(ko)
|
2016-05-16 |
2024-03-21 |
인타르시아 세라퓨틱스 인코포레이티드 |
글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
CN107561168A
(zh)
*
|
2016-06-30 |
2018-01-09 |
山东新时代药业有限公司 |
一种聚乙二醇化促胰岛素分泌肽类似物的分析检测方法
|
|
ES2828526T3
(es)
|
2016-11-07 |
2021-05-26 |
Novo Nordisk As |
Esteres activos DCHBS de compuestos PEG y sus usos
|
|
WO2018106641A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Pyrazoles for the treatment of demyelinating diseases
|
|
WO2018106646A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Aminotriazoles for the treatment of demyelinating diseases
|
|
WO2018106643A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic azoles for the treatment of demyelinating diseases
|
|
JP7301741B2
(ja)
|
2016-12-07 |
2023-07-03 |
ラ ファーマシューティカルズ インコーポレイテッド |
補体活性のモジュレータ
|
|
AU2018206539A1
(en)
|
2017-01-03 |
2019-07-18 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
|
HRP20220223T1
(hr)
|
2017-01-11 |
2022-04-29 |
Alkermes, Inc. |
Biciklički inhibitori histon deacetilaze
|
|
FR3061715B1
(fr)
*
|
2017-01-12 |
2021-07-30 |
Institut National Univ Jean Francois Champollion |
Peptide immunomodulateur
|
|
WO2018165462A1
(en)
*
|
2017-03-08 |
2018-09-13 |
Intarcia Therapeutics, Inc |
Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
|
|
AR112015A1
(es)
|
2017-06-09 |
2019-09-11 |
Novo Nordisk As |
Composiciones sólidas para administración oral
|
|
US11225475B2
(en)
|
2017-08-07 |
2022-01-18 |
Alkermes, Inc. |
Substituted pyridines as inhibitors of histone deacetylase
|
|
BR112020002804A2
(pt)
|
2017-08-24 |
2020-07-28 |
Novo Nordisk A/S |
composição farmacêutica líquida, e, kit
|
|
CA3151394C
(en)
*
|
2017-09-19 |
2023-10-03 |
Immunwork Inc. |
Pharmaceutical constructs with enhanced binding affinity with albumin
|
|
CA3078652A1
(en)
|
2017-10-12 |
2019-04-18 |
Novo Nordisk A/S |
Semaglutide in medical therapy
|
|
AR114353A1
(es)
|
2018-02-02 |
2020-08-26 |
Novo Nordisk As |
Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
|
|
SMT202200352T1
(it)
|
2018-04-05 |
2022-09-14 |
Sun Pharmaceutical Ind Ltd |
Analoghi del glp-1 innovativi
|
|
PE20210473A1
(es)
*
|
2018-05-04 |
2021-03-08 |
Novo Nordisk As |
Derivados de gip y usos de estos
|
|
TWI829687B
(zh)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|
|
CN109111361A
(zh)
*
|
2018-10-08 |
2019-01-01 |
扬州工业职业技术学院 |
一种一步法高效制备十二烷基二酸单叔丁酯的方法
|
|
CN109134257A
(zh)
*
|
2018-10-08 |
2019-01-04 |
扬州工业职业技术学院 |
一种两步法制备高纯度十二烷基二酸单叔丁酯的方法
|
|
WO2020118843A1
(zh)
*
|
2018-12-12 |
2020-06-18 |
四川利通科创生物医药科技有限公司 |
一种glp-1突变体及其制备方法和用途
|
|
EP3914383B1
(en)
|
2019-01-24 |
2026-07-15 |
Novo Nordisk A/S |
Method of dry granulation using a roller compactor
|
|
WO2020180534A1
(en)
|
2019-03-01 |
2020-09-10 |
President And Fellows Of Harvard College |
Methods and compositions for protein delivery
|
|
KR20220004066A
(ko)
|
2019-04-03 |
2022-01-11 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
약물 전달용 이온성 액체
|
|
ES2973767T3
(es)
|
2019-06-04 |
2024-06-24 |
Ra Pharmaceuticals Inc |
Tratamiento de enfermedades inflamatorias con inhibidores del complemento
|
|
WO2021070202A1
(en)
*
|
2019-10-09 |
2021-04-15 |
Prasad Alaparthi Lakshmi |
A method for preparing glp-1 analogue by solid-phase peptide synthesis
|
|
CA3154744A1
(en)
|
2019-11-06 |
2021-05-14 |
Sarah FRIEDRICH |
Glp-1 receptor agonists in dementia
|
|
JP2023502004A
(ja)
|
2019-11-07 |
2023-01-20 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ－１作動薬、ｓｇｌｔ２阻害剤、およびｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む固形組成物
|
|
CN114980864A
(zh)
|
2019-11-22 |
2022-08-30 |
哈佛大学校长及研究员协会 |
用于药物递送的离子液体
|
|
EP4069726A4
(en)
|
2019-12-04 |
2024-03-20 |
The Scripps Research Institute |
GLP2 RECEPTOR AGONISTS AND METHOD OF USE
|
|
WO2021136223A1
(en)
|
2019-12-31 |
2021-07-08 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Fusion proteins of glp-1 and gdf15 and conjugates thereof
|
|
IL294521A
(en)
|
2020-02-18 |
2022-09-01 |
Novo Nordisk As |
glp-1 compounds and their uses
|
|
GB202003762D0
(en)
*
|
2020-03-16 |
2020-04-29 |
Heptares Therapeutics Ltd |
GLP receptor agonists
|
|
CN115461044B
(zh)
|
2020-04-29 |
2025-06-10 |
诺和诺德股份有限公司 |
包含glp-1激动剂和组氨酸的固体组合物
|
|
CN118754965A
(zh)
|
2020-05-29 |
2024-10-11 |
北京拓界生物医药科技有限公司 |
Glp-1和gip受体双重激动剂化合物及其应用
|
|
WO2022018748A1
(en)
*
|
2020-07-18 |
2022-01-27 |
Dr. Reddy's Laboratories Limited |
Improved purification process of semaglutide
|
|
AU2021312323A1
(en)
|
2020-07-22 |
2023-02-02 |
Novo Nordisk A/S |
Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
|
|
CA3193453A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Polypeptide conjugates and methods of uses
|
|
JP7484018B2
(ja)
|
2020-11-06 |
2024-05-15 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ－１プロドラッグおよびその使用
|
|
TW202620039A
(zh)
*
|
2020-12-18 |
2026-05-16 |
丹麥商諾佛 儂迪克股份有限公司 |
Ｇｌｐ－１及澱粉素受體之共促效劑之用途
|
|
CN114685644A
(zh)
*
|
2020-12-29 |
2022-07-01 |
苏州康宁杰瑞生物科技有限公司 |
一种人glp-1多肽变体及其应用
|
|
WO2022175384A1
(en)
*
|
2021-02-17 |
2022-08-25 |
Fundación Universidad Católica De Valencia San Vicente Mártir |
Small-molecule agents with antiviral activity against rna viruses
|
|
AU2022289610A1
(en)
|
2021-06-09 |
2024-01-25 |
The Scripps Research Institute |
Long-acting dual gip/glp-1 peptide conjugates and methods of use
|
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|
|
JP2024538700A
(ja)
|
2021-10-08 |
2024-10-23 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
薬物送達のためのイオン液体
|
|
CA3237751A1
(en)
|
2021-11-10 |
2023-05-19 |
Tyler Brown |
Ionic liquid compositions
|
|
CN116650424A
(zh)
*
|
2022-01-06 |
2023-08-29 |
鸿绪生物医药科技（北京）有限公司 |
新型多肽制剂及其治疗用途
|
|
TW202330584A
(zh)
|
2022-01-20 |
2023-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
前藥及其用途
|
|
EP4323413A4
(en)
|
2022-03-30 |
2025-10-15 |
Beijing Ql Biopharmaceutical Co Ltd |
LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
|
|
US20250304645A1
(en)
|
2022-05-10 |
2025-10-02 |
Novo Nordisk A/S |
Prodrugs of GLP-1 Polypeptide and Uses Thereof
|
|
WO2024003313A1
(en)
|
2022-06-30 |
2024-01-04 |
Sanofi |
New peptides as selective il-23 receptor antagonists
|
|
CN115785249B
(zh)
*
|
2022-10-13 |
2023-07-21 |
江苏师范大学 |
一类glp-1类似物及其应用
|
|
TW202421645A
(zh)
|
2022-11-25 |
2024-06-01 |
丹麥商諾佛 儂迪克股份有限公司 |
如ｇｌｐ—１之肽治療劑的口服投與
|
|
CN121001710A
(zh)
|
2022-12-30 |
2025-11-21 |
阿尔吉法玛公司 |
提高口服多肽治疗剂的全身生物利用度的组合物和方法
|
|
EP4720106A1
(en)
*
|
2023-05-26 |
2026-04-08 |
Gubra A/S |
Secretin-derived glp1r selective agonists
|
|
WO2025098422A1
(zh)
*
|
2023-11-07 |
2025-05-15 |
深圳信立泰药业股份有限公司 |
多重受体共激动剂化合物及其制备方法与应用
|
|
WO2026072611A1
(en)
*
|
2024-09-24 |
2026-04-02 |
Eli Lilly And Company |
Tirzepatide binding molecules, and uses thereof
|
|
GB202418179D0
(en)
|
2024-12-11 |
2025-01-22 |
Algipharma As |
Compositions and methods
|
|
GB202418172D0
(en)
|
2024-12-11 |
2025-01-22 |
Algipharma As |
Compositions and methods
|